Azienda Ospedaliera Universitaria Policlinico
16
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
6.3%
1 terminated/withdrawn out of 16 trials
83.3%
-3.2% vs industry average
38%
6 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Effect of Infections and Global DNA Methylation on Frailty Trajectories in Hospitalized Older Patients (INFRAGEN)
Role: collaborator
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
Role: collaborator
Nutraceuticals and Functional Foods
Role: collaborator
Key Performance Indicators for the Assessment of NSCLC Patients Pathway
Role: collaborator
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy
Role: collaborator
The MORDIS Study Clinical Investigational Plan
Role: collaborator
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Role: collaborator
Evaluation of Different Disease Control Indices in Children With Asthma and Rhinitis
Role: collaborator
Montelukast in Children With Wheezing
Role: collaborator
Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients
Role: collaborator
Multicentric Prospective Randomized Trial on Surgery Versus Standard Medical Care in Type 2 Diabetic Patients BMI 30-35
Role: collaborator
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
Role: lead
Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
Role: lead
Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants
Role: lead
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
Role: lead
Deferment of Imaging for Pulmonary Embolism
Role: lead
All 16 trials loaded